For much of modern oncology, success has been measured in survival statistics.

Five-year survival rates. Overall survival. Progression-free survival; almost every new cancer treatment is underpinned by the goal of helping more people live longer after a cancer diagnosis. It's a mission that has transformed countless lives.

But with more people than ever living with and beyond cancer, attention is shifting towards the quality of what those extra months and years look like for the patient, as well as the quantity.

The idea of helping patients live, and live well, runs through this issue. From our cover feature on the growing role of liquid biopsies in monitoring cancer, to the continued evolution of antibody-drug conjugates, and the changing face of cancer in younger adults, each of this edition’s contributors is connected by the shared ambition of improving lives beyond the “finish line” of treatment.

On a sadder note, we want to dedicate this issue to our beloved team member and dear friend, Lynette Arnell, who recently passed away. She was a fundamental piece of the Deep Dive puzzle, and she will be sorely missed.

Best,

Eloise McLennan
Deep Dive editor